AACR 2021 | Molecular profiling of exceptional responders to cancer therapy

Elizabeth Plimack • 7 Apr 2021

AACR 2021

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, explores the findings of a single-center analysis of exceptional responders to cancer therapy from the Fox Chase Cancer Center. In this study, mutations in DNA damage repair pathway genes were frequently present in exceptional responders, suggesting a role of increased genomic instability which may have contributed to exceptional responses to standard anticancer therapies in the patients studied. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Elizabeth Plimack, MD, MS, has participated in consultancy work, scientific advisory boards and or data safety monitoring with Aveo, BMS, Calithera, Genentech, Janssen, MEI Pharma, Merck, Pfizer, Seattle Genetics, AstraZeneca and Infinity Pharma; has received honoraria from Clinical Care Options, Creative Educational Concepts, CUA, JADPRO, PER, Research to Practice, Total CME and The Hawaii Society of Clinical Oncology; and has received grants for clinical research from Astellas, BMS, Genentech and Merck.